Brief Summary

This is a single-arm feasibility study that is recruiting 40 patients with histologically-proven localized prostate cancer and MRI-defined lesion(s). Participants in this study will get MR-guided radiotherapy boost to MRI visible tumour before or after whole gland radiation. Participants will be followed-up as per standard of care schedule up to 5 years post-treatment.

Official Title

MR-guided Tumour Boost With Stereotactic Body Radiotherapy in Prostate Cancer

Eligibility Inclusion Criteria

- Histologically-proven localized prostate cancer.
- Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor)
- Low-risk: cT1-T2a, PSA <10, and Gleason score 6
- Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7
- High-risk limited to 1 risk factor: >T2, PSA >20, or Gleason score >7
- Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/< 1/3 total prostate volume
- Planned for EBRT (+/- ADT)
- ECOG 0 or 1
- 18 years of age or older
- Ability to provide written informed consent to participate in the study

Eligibility Exclusion Criteria

- Prior radiotherapy to pelvis
- Radiological evidence of regional or distant metastases at the discretion of the treating physician.
- Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
- Ataxia Telangectasia and SLE
- Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury
- Severe claustrophobia